Join a Clinical Trial
Whether you are eligible for a research study depends on many things. There are specific requirements to be in research studies. These requirements are different for each clinical trial.
Clinical Trial Details
A Study to Investigate LYL797 in Adults With Solid Tumors
Complete Title: A Phase 1 Study to Assess the Safety and Efficacy of LYL797, ROR1-Targeting CAR T Cells, in Adults with Relapsed and/or Refractory Solid-Tumor Malignancies
Trial Phase: I
Investigator: Jennifer Specht
This study will evaluate the safety and tolerability of LYL797, a ROR1-targeted CAR T-cell therapy, in patients with ROR1+ relapsed or refractory triple negative breast cancer (TNBC) or non-small cell lung cancer (NSCLC). The first part of the study will determine the safe dose for the next part of the study, and will enroll TNBC and NSCLC patients. The second part of the study will test that dose in additional TNBC and NSCLC patients.
Keywords:
- Breast Cancer
- Lung Cancer
- Lung Carcinoma, Non-Small-Cell (NSCLC)
- Triple Negative Breast Neoplasms
Disclaimer: We update this information regularly. However, what you read today may not be completely up to date.
Contact Us
If you are seeking to schedule an appointment, we are here to help. You can either call us or fill out our online appointment request form.
Adult
I
Jennifer Specht
RG1122382
NCT05274451
A Phase 1 Study to Assess the Safety and Efficacy of LYL797, ROR1-Targeting CAR T Cells, in Adults with Relapsed and/or Refractory Solid-Tumor Malignancies
Breast Cancer
Lung Cancer
Lung Carcinoma, Non-Small-Cell (NSCLC)
Triple Negative Breast Neoplasms